Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Beam Therapeutics (BEAM) Change in Cash (2019 - 2025)

Historic Change in Cash for Beam Therapeutics (BEAM) over the last 7 years, with Q3 2025 value amounting to -$14.1 million.

  • Beam Therapeutics' Change in Cash rose 7723.96% to -$14.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $37.9 million, marking a year-over-year decrease of 3584.87%. This contributed to the annual value of -$154.5 million for FY2024, which is 17760.34% down from last year.
  • According to the latest figures from Q3 2025, Beam Therapeutics' Change in Cash is -$14.1 million, which was up 7723.96% from -$245.8 million recorded in Q2 2025.
  • Beam Therapeutics' Change in Cash's 5-year high stood at $400.0 million during Q3 2021, with a 5-year trough of -$263.2 million in Q1 2022.
  • Its 5-year average for Change in Cash is $5.1 million, with a median of -$18.6 million in 2023.
  • As far as peak fluctuations go, Beam Therapeutics' Change in Cash skyrocketed by 1544411.76% in 2021, and later tumbled by 542276.37% in 2025.
  • Over the past 5 years, Beam Therapeutics' Change in Cash (Quarter) stood at -$54.1 million in 2021, then skyrocketed by 240.9% to $76.3 million in 2022, then soared by 249.97% to $266.9 million in 2023, then crashed by 80.01% to $53.4 million in 2024, then tumbled by 126.52% to -$14.1 million in 2025.
  • Its Change in Cash stands at -$14.1 million for Q3 2025, versus -$245.8 million for Q2 2025 and $244.4 million for Q1 2025.